Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-442 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TAK-442 10 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events. |
| TAK-442 20 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 40 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 40 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 80 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 80 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 160 mg QD | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| TAK-442 120 mg BID | EXPERIMENTAL | Added with standard care for recurrent ischemic events |
| Placebo | PLACEBO_COMPARATOR | Added with standard care for recurrent ischemic events |
| Enoxaparin 30 mg BID | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-442 | DRUG | Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks. |
| Placebo | DRUG | Stages I, II \& III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks. |
| Enoxaparin | DRUG | Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days. |
Inclusion Criteria: * Has been hospitalized for acute coronary syndrome * Is able to initiate study drug if: * The index event occurred within the past 7 days (the date of initial hospitalization will be utilized for the date on which the index event occurred), and * The final acute medical or...
TAK-442 is an investigational small molecule being studied for the prevention and treatment of venous thromboembolism and for use in patients with acute coronary syndrome. It was evaluated in Phase 2 clinical trials for these cardiovascular conditions, though it is not approved and remains in clinical development.
TAK-442 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company sponsored the Phase 2 clinical trials for this investigational cardiovascular drug.
TAK-442 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in venous thromboembolism and one in acute coronary syndrome. The drug is investigational and has not been approved by regulatory authorities.
TAK-442 has completed two Phase 2 trials. NCT00641732 evaluated its efficacy and safety in 1,045 subjects undergoing total knee replacement for venous thromboembolism. NCT00677053 assessed its safety and efficacy in 2,753 subjects with acute coronary syndromes across multiple countries.
TAK-442 is the sole name provided for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information.